

AMERICAN COLLEGE
of RHEUMATOLOGY
Empowering Rheumatology Professionals

Call for Abstracts

GUIDELINES FOR SUBMISSION

50TH
ANNIVERSARY

ACR

Pediatric Rheumatology

MARCH 18-21, 2026 • MINNEAPOLIS, MN SYMPOSIUM

Submit your Abstract for the 2026 Pediatric Rheumatology Symposium!

This is your complete guide for submitting an abstract for the 2026 Pediatric Rheumatology Symposium (PRSYM) in Minneapolis, MN on March 18-21. ***Please read this entire guide before you begin the submission process.***

PRSYM is the premier educational event for rheumatologists, physicians, and other healthcare providers who care for pediatric patients with rheumatic diseases; clinical investigators; physician-scientists; and those interested or engaged in research in the field of pediatric rheumatic diseases.

NEW THIS YEAR:

- PRSYM 2026 will be in person in Minneapolis, MN, there will **not** be a live streaming component.
- The ACR will not offer CME credit for any abstract session or posters. Owners and employees of ACCME-defined ineligible companies may submit and present abstracts.

The American College of Rheumatology (ACR) and the Association of Rheumatology Professionals (ARP) invite you to submit an abstract and take advantage of the opportunity to have your work peer reviewed by experts in the field. If accepted, your abstract will be published in an online supplement of [Arthritis & Rheumatology, one of the ACR's research journals](#).

Important Dates

Abstract Submission

Wednesday, October 1	Abstract Submission Site Opens
Wednesday, November 12	Abstract Submission Site Closes (Noon ET)
Mid-December	Presenting Author Notification
February 18	Accepted Abstract Withdrawal Deadline

Housing

Wednesday, February 18	Housing Deadline
------------------------	------------------

PRSYM

Wednesday, March 18	Abstract Embargo Lifted (6:00 PM CT)
Thursday, March 19	Abstract Plenary Session (2:30 – 3:30 PM CT)
	Abstract Breakout Presentations (5:10 – 5:40 PM CT)
	Abstract Poster Session (6:00 – 7:00 PM CT)
Friday, March 20	Abstract Plenary Session (2:30 – 3:00 PM CT)
	Abstract Breakout Presentations (4:30 – 5:00 PM CT)
	Abstract Poster Session (5:00 – 6:00 PM CT)
	Awards Dinner (6:30 – 8:00 PM CT)
Saturday, March 21	Abstract Plenary Session (11:00 AM – 12:00 PM CT)

Contents

PART I: ABSTRACT SUBMISSION4

 ELIGIBILITY4

 ABSTRACT SUBMITTER/PRESENTER EXPECTATIONS.....4

AWARDS AND SCHOLARSHIPS.....5

ABSTRACT SUBMISSION INSTRUCTIONS/GUIDELINES5

 SUBMITTING AN ABSTRACT5

 ABBREVIATIONS.....5

 ABSTRACT CHARACTER LIMIT.....6

 ABSTRACT TITLE6

 ACR DISEASE CRITERIA.....6

 AUTHORS7

 CONTENT0

 IMAGES, TABLES, AND GRAPHICS0

 DISCLOSURE POLICY0

 DISCLOSURE STATEMENT SUBMISSION PROCESS1

 INVOLVEMENT OF INDIVIDUALS NOT LISTED AS AUTHORS.....1

 MULTIPLE SUBMISSIONS OF SAME STUDY2

 PRESENTATION FORMATS2

 PRODUCT NAME USAGE2

 RESEARCH INVOLVING ANIMALS2

 RESEARCH INVOLVING HUMAN SUBJECTS2

 REVISIONS.....2

 STUDY DESIGN ABSTRACT SUBMISSIONS3

 STUDY SPONSOR STATEMENTS3

 WITHDRAWALS3

 Need Help?.....3

ABSTRACT REVIEW AND NOTIFICATION3

 ABSTRACT REVIEW3

 ABSTRACT ACCEPTANCE/REJECTION NOTIFICATIONS4

REGISTRATION & HOUSING.....4

PART II: ABSTRACT SUBMISSION4

 ABSTRACT EMBARGO POLICY.....4

 PRESENTATION FORMATS.....5

 PLENARY PRESENTATION5

 PLENARY PRESENTATION SLIDE REQUIREMENTS.....5

 POSTER BREAKOUT PRESENTATION5

 POSTER SESSION PRESENTATION.....6

 ACR POSTER PRESENTER EXPECTATIONS.....6

PRESENTING AUTHOR RESPONSIBILITIES7

 ABSTRACT SESSION SCHEDULE CONFLICTS POLICY8

 PRESENTING AUTHOR AFFIRMATIONS.....8

SCIENTIFIC INTEGRITY AND ACR POLICY REGARDING THIRD-PARTY BIAS 8

PART III: ABSTRACT PERMISSIONS POLICIES 9

ABSTRACT EMBARGO POLICY 9

COPYRIGHT POLICY 9

MEDIA..... 9

ABSTRACT PERMISSIONS AND REPRINTS 10

REPRODUCING ACR ABSTRACTS FOR DISSEMINATION..... 10

ACR POSTER PRESENTATIONS..... 12

MEDIA ACCESS..... **ERROR! BOOKMARK NOT DEFINED.**

ATTENDEE PHOTOGRAPHS AND VIDEO RECORDING POLICY **ERROR! BOOKMARK NOT DEFINED.**

DISCLOSURE AND CONTENT USE 13

USE OF THE ACR NAME 13

USE OF THE ACR SCIENTIFIC PROGRAM CONTENT 13

PUBLICATION 14

Part I: Abstract Submission

ACR Call for Abstracts

The PRSYM program includes content related to the clinical practice and teaching of rheumatology and the basic and translational science that contributes to the understanding of disease pathogenesis, the mechanisms and efficacy of therapeutics, and the delivery of healthcare to pediatric patients with musculoskeletal and rheumatic disease.

Eligibility

Who Is Eligible to Submit?

- Members and non-members of the ACR and ARP are eligible to submit an abstract.

What Types of Abstracts Are Eligible for Submission?

- Abstracts that have been previously accepted and/or presented at other medical meetings are eligible for submission. These abstracts will go through the same peer review process as any other abstracts.
- Abstracts describing original basic and clinical science related to the broad area of rheumatic diseases may be submitted.
- Abstracts reporting results of a clinical trial will be required to identify the trial phase.
- Any work with human or animal subjects reported in submitted abstracts must comply with the guiding principles for experimental procedures found in the [Declaration of Helsinki](#) of the World Medical Association.

What Types of Abstracts Are Not Eligible for Submission?

- Abstracts should not report results that have been previously presented at an ACR/ARP Annual Meeting.
- Abstracts that report work that has been accepted for publication as a [manuscript](#) (e.g., full-length article, brief report, case report, concise communication or letter to the editor, etc.) prior to the submission deadline of **noon ET on November 12, 2025**, are ineligible for consideration.
- Multiple abstracts may not be submitted for one study unless substantially different research questions are being addressed in each abstract.
- Case reports are not considered appropriate and will not be reviewed.

Abstract Submitter/Presenter Expectations

- Pay a processing fee for each abstract submission (see next section). Abstract processing fees must be in U.S. funds and are non-refundable. The ACR will provide a receipt but **does not supply invoices for payments received**.
- By submitting your abstract, you agree to present the abstract if it is selected for presentation during an oral or poster abstract presentation at the 2026 Pediatric Rheumatology Symposium in Minneapolis, MN.
- If your abstract can only be presented as a poster, please check the appropriate box during the submission process. **This is your only opportunity to indicate your preference for a poster.**
- Select the most appropriate category to submit the abstract based on the most relevant topic.
- **No changes may be made to a submission after the deadline of November 12 at noon ET.** However, you will be able to access the submission portal to view your completed abstract submission. You may print a copy of your submission fee receipt.

Submitting an ACR Abstract

Before submitting, please review the abstract submission instructions provided in this guide. Visit the abstract [online submission site](#) to get started.

Abstract Submission Deadline is November 12, 2025 at 12 PM ET!

Abstract Submission Processing Fee

The fee for submitting each abstract is **\$75**. The ACR accepts electronic payment only in the form of MasterCard, Visa, or American Express. Abstract processing fees must be in U.S. funds and are non-refundable—no exceptions. There are no refunds for rejected or withdrawn abstracts.

Submitters from countries with low-income and lower-middle-income economies as determined by the [World Bank](#), for whom the abstract submission fee would cause undue hardship, may request that the abstract submission fee be waived. Please contact abstracts@rheumatology.org to provide proof of residency. **Requests for this fee waiver must be submitted to abstracts@rheumatology.org by Wednesday, November 5, 2025.**

SUBMISSION DEADLINE: *Wednesday, November 12, 2025 at noon ET—no exceptions.* *No changes may be made to your submission, including author information, after the deadline.*

Awards and Scholarships

The ACR and ARP encourage the submission of abstracts by presenting authors who are pre-doctoral and post-doctoral students, residents, medical students, or fellows in training.

The Rheumatology Research Foundation is the largest private funding source of rheumatology training and research programs in the United States. The Foundation offers a wide range of awards and grants aimed at recruiting the brightest young minds to the field, providing quality education and training, and supporting essential research that will lead to major advances in treating patients.

The Foundation provides outstanding students and residents the opportunity to attend the 2026 Pediatric Rheumatology Symposium. Check back soon for updated Request for Applications and deadline details.

Learn more about [Foundation Awards & Grants](#) or contact the Foundation at the Rheumatology Research Foundation at foundation@rheumatology.org

Abstract Submission Instructions/Guidelines

Submitting an Abstract

- All abstracts must be submitted online.
- The link to submit abstracts will be available on the [PRSYM webpage](#) starting October 1.
- Submitters will be able to access complete submission instructions and guidelines via the online submission site.

Abbreviations

- Use standard abbreviations. A [list of acronyms for many common rheumatology terms](#) has been developed by an international group of rheumatology journal editors.
- Place special or unusual abbreviations in parentheses after the first time the full word appears.
- Do not abbreviate chemical compounds in the title of the abstract.
- Use numerals to indicate numbers, except when beginning sentences.

Abstract Submission Deadline is November 12, 2025 at 12 PM ET!

Abstract Character Limit

- **Title** character limit: 250 characters, excluding spaces
- **Body** character limit: 2,750 characters, which EXCLUDES the title, names of authors/co-authors, authors' affiliations, spacing, and disclosures.
- **Image, table, and/or graphic** limit: There is a limit of three image, table, and/or graphic uploads per submission. Uploaded tables and/or graphics do not count towards the character limit.
- References in the abstract body will be included in the character count.
- Abstracts exceeding the character limit will be considered “incomplete.” Abstracts marked “incomplete” at the close of the submission deadline will be ineligible for review.

Abstract Title

- Enter the title **in the title field only** and do not enter the title in the body of the abstract. When entered in the title field only, titles DO NOT count towards the 2,750 abstract body character limit.
- The title character limit is 250 characters, excluding spaces.
- Take special care when entering your title, as it may be published exactly as submitted.
- Titles should be brief, clearly indicating the nature of the presentation.
- Include only [commonly used acronyms](#) in the abstract title.
- Do not include a trial group name or acronym in the abstract title.
- Registry names may be included in the title.
- When entering the title, use mixed case (do not use all caps OR all lowercase). Do not put a period at the end of the title. For example:

Correct:

- **This Is a Properly Formatted Abstract Title**

Incorrect:

- **THIS IS AN IMPROPERLY FORMATTED ABSTRACT TITLE**
- **This is an improperly formatted abstract title**
- **This is an improperly formatted abstract title.**

ACR Disease Criteria

The ACR name may not be used to describe criteria unless:

- 1) The criteria have been officially endorsed by the ACR and you are using the name of the criteria as published;
OR
- 2) *You have obtained the ACR's permission* to use the ACR name in relation to a project that is in progress but not yet completed.

Incorrect use of the ACR name in regard to criteria will result in the removal of an abstract from the PRSYM Abstract

Abstract Submission Deadline is November 12, 2025 at 12 PM ET!

Supplement, and a correction will be required to be made on the poster or presentation. Investigators involved in ACR-supported, in progress criteria projects who wish to use the ACR name should contact abstracts@rheumatology.org for further information.

Authors

- Employees or owners of ineligible companies may be the presenting author of an abstract.
- To qualify for authorship, individuals must have made substantial contributions to study conception and design; and/or substantial contributions to acquisition of data; and/or substantial contributions to analysis and interpretation of data.
- **You may not add additional authors after the deadline has passed.**
- Do not list authors or financial relationships in the body of the abstract.
- Please consult with your co-authors on how their names should appear prior to submission. You will not be able to make changes after the submission deadline.
- All authors must disclose any relevant financial relationship(s) at the time of submission.
- There is no limit on the number of authors that may be included in the author block. However, the submission system is only able to support a maximum of 50 authors. If you have more than 50 authors on your abstract, contact abstracts@rheumatology.org for further instructions.
- See the **Disclosure Policy** section below for additional author identification instructions.

Content

- Do not use new technical words, laboratory slang, words not defined in dictionaries, or abbreviations or terminology not consistent with internationally accepted guidelines.
- Refer to the list of [commonly used acronyms](#) for recommendations on acceptable terms for scientific communication.
- Define special or unusual abbreviations the first time they are used.
- Omit all names and geographical references in the body of the abstract.
- Organize content in sections as follows:
 - **Background/Purpose:** Background or statement of purpose
 - **Methods:** Methods, materials, and analytical procedure used*
 - **Results:** Summary of the results in sufficient detail to support conclusion (never “results will be discussed”)
 - **Conclusion:** Conclusions reached

****Please Note:** In order to make the description of patients as clear as possible and to facilitate comparisons with other studies, the Methods section should include, whenever possible, a short paragraph detailing the proportion of patients who satisfy the ACR classification criteria for the particular disease described.*

The submission form contains separate fields for each section, where content may be copy/pasted or typed directly. **You do not need to include the section titles.** After entering your submission text, you may upload images and captions separately.

Images, Tables, and Graphics

- Up to three images are allowed. Uploaded tables and/or graphics do not count towards the character limit.
- The maximum allowable size of each image is 10 MB.
- Images will be accepted as JPG or GIF.
- **It is recommended that all tables be uploaded as an image.** This will help us ensure consistent and accurate output of your table at the time of publication.
- **IMPORTANT:** Images, tables, and/or graphics exceeding the total limit of three may be marked “incomplete” at the close of the submission deadline and will be ineligible for review.

Disclosure Policy

- The ACR is committed to ensuring the PRSYM 2026 abstract program is scientifically balanced. All content will be validated via rigorous peer review, and the ACR will collect and publish all author's disclosures according to ACCME criteria and standards.
- As a CME provider accredited by the [Accreditation Council for Continuing Medical Education](#) (ACCME), the ACR must ensure balance, independence, objectivity, and scientific rigor in all its educational activities.
- The ACR requires that all individuals (moderators, reviewers, authors, planners, and others) who are in a position to control content of the abstract program disclose to the planning committee, ACR, and audience any financial relationships with ineligible companies.

- **An ineligible Company** is considered any entity whose primary business is producing, marketing, re-selling, or distributing healthcare products used by or on patients.
- **Relevant Financial Relationships** exist between persons in control of the content and an ineligible company during the past 24 months. The content of the education is related to the products of an ineligible company with whom the person has a financial relationship.
- If no financial relationships exist, individuals **MUST STATE** that **NONE** exists to reflect that the question was asked and answered.

Nature of Financial Relationship

None: Has no relevant financial relationship(s) with ineligible companies to disclose.

1. Advisor or Review Panel member
2. Consultant
3. Employee
4. Officer or Board Member
5. Grant/Research Support
6. Speaker/Honoraria includes speakers bureau, symposia, and expert witness
7. Independent Contractor
8. Ownership Interest
9. Royalties
10. Intellectual Property / Patents
11. Stock options or bond holdings in a for-profit corporation or self-directed pension plan
12. Other Financial or Material Support

Disclosure Statement Submission Process

- Abstracts will not be eligible for review without proper completion of the disclosure of financial relationships section on the submission form.
- Failure to disclose correctly may lead to corrective action as deemed appropriate by the ACR or ARP leadership.
- The abstract review process is blind. The disclosure information you provide will not influence the review of your abstract.
- **Submitters may send an automated email from within the submission site to each author, inviting authors to complete their disclosures directly.**
- Presenting authors/submitters are also permitted to enter the disclosure information on behalf of each co-author during the online submission process.
 - Keep in mind that all disclosure information must be entered in the online submission site—the ACR does not accept paper disclosure statement forms.
- **Whether a submitter enters all disclosures or invites authors to submit disclosures, it is the responsibility of the submitter to ensure all disclosures are completed.**
- Accepted disclosures collected at the time of submission will be published on the [ACR PRSYM website](#).

Involvement of Individuals Not Listed as Authors

- Names of all individuals who had a substantial role in the study or abstract preparation but are not included in the list of authors (such as a medical writer) may be disclosed in the body of the abstract.
- For each individual, please describe the activity or activities (e.g., one or more of the activities included in the [authorship criteria](#) list).

Multiple Submissions of Same Study

The same study should not be submitted as multiple abstracts. Therefore, if the abstracts in question are not different enough to be considered separate studies (specifically, if they address the same research question or present the same results), they may all be rejected.

Presentation Formats

- Abstracts are considered for plenary presentation, poster breakout presentation, or poster session presentation.
- The presenting author does not need to be the first author but must be a listed author.
- As English is the designated language for the meeting, the presenting author is required to speak English when presenting.
- For plenary or poster breakout sessions, only one author may present the abstract.
- If your abstract can only be presented as a poster, please check the appropriate box during the submission process.

Product Name Usage

- The non-proprietary (generic/scientific) name should be used in your abstract.
- The proprietary drug name may appear once in parentheses in the title only. It may not appear in the body of the abstract.
- If a drug has not received FDA approval, only the non-proprietary name may be used in the title and abstract content.
- Failure to comply will result in disqualification of your submission.

Research Involving Animals

The Institutional Animal Care and Use Committee (IACUC) of an institution, or a comparable body depending on country, ensures the humane treatment of animals used for research and education. If your research involved animals, you will be required to check a box during the submission process to attest that you have received the appropriate approval.

Research Involving Human Subjects

An Institutional Review Board (IRB), or a comparable ethical review board depending on country, protects the rights and welfare of people involved in research. If your research involved human subjects, you will be required to check a box during the submission process to attest that you have received the appropriate ethical review board approval.

Revisions

- You may return to the online submission site to revise your abstract until **noon ET on Wednesday, November 12, 2025**.
- After this date/time, the submission site will close and no additional changes, edits, revisions, etc. can be made to the title, content, author, or disclosure information—***no exceptions***.
- Proofread carefully to avoid errors prior to submission.

- Selected abstracts will be published online *exactly* as submitted.
- Should a submission contain errors or the omission of contributing author names after the deadline, presenters may opt to have the abstract withdrawn. Refer to the [Withdrawals](#) section of this guide for instructions.

Study Design Abstract Submissions

All abstracts must contain data and the interpretation of data. Therefore, a study design abstract that merely describes a prospective study is not eligible for submission.

A study design abstract could be appropriate for submission if, like any other submission, it describes a hypothesis, description of methodology, data, interpretation of data, etc. For example, one study design could be compared to another. Submit an abstract to a category based on the disease for which the study design is most relevant.

Study Sponsor Statements

- For abstracts about studies that were funded by a pharmaceutical company, biotech company, or other commercial enterprise, a "Role of the Study Sponsor" (or Sponsors) statement must be included.
- This statement describes the commercial entity's role in the conduct and reporting of the study.
- **IMPORTANT:** This applies only to **commercial enterprises**. It does not apply to **government entities** such as the National Institutes of Health (NIH) or its equivalent funding agencies in other countries, or to public or private foundations.
- Study sponsor statements will be published in electronic version only on the [ACR website](#).
- **Do not include a sponsor statement in the text of your abstract.**

Withdrawals

- After **November 12**, presenting authors may submit a request to have an abstract withdrawn.
- All requests can only be made by the **presenting author** and must be submitted via email to: withdrawn@rheumatology.org.
- **Withdrawal requests must include the following:**
 - Abstract ID Number
 - Abstract Title
 - Presenting Author's Name
- Removal of a withdrawn abstract from the online supplement of *Arthritis & Rheumatology* cannot be guaranteed if the request is received after **Wednesday, February 18**.

Need Help?

- Should you need technical support, please email support@GoCadmium.com or call (410) 638-9239 between the hours of 9 AM–9 PM ET, Monday–Friday to reach a support specialist.
- For **general guideline inquiries** regarding abstract submission, email abstracts@rheumatology.org.

Abstract Review and Notification

Abstract Review

- After the submission deadline, completed abstracts will be peer reviewed by the PRSYM abstract

committee according to subject categories.

- Incomplete abstracts cannot be processed and will not be reviewed.
- Revisions will not be accepted after the submission deadline—*no exceptions*.
- All reviewers are required to sign a confidentiality agreement.
- All abstracts will be blinded for review, i.e., reviewed without knowledge of the author(s), institution(s), or disclosure information.
- Accepted abstracts will be selected as either a plenary session, short oral presentation, or a poster presentation.

Abstract Acceptance/Rejection Notifications

- Both presenting authors and co-authors will receive initial notification of acceptance/rejection.
- After initial notification, co-authors will be referred to the presenting author for any additional questions. No further correspondence will occur between the ACR and co-authors unless the presenting author has been unresponsive after 30 days from the first notification.

Registration & Housing

- Submission or acceptance of an abstract *does not register you or ensure hotel accommodations* for the Pediatric Rheumatology Symposium. All presenting authors are required to register for the meeting, pay the appropriate registration fees, and arrange hotel accommodations.
- As abstract presentation dates will not be finalized until December, presenting authors should plan to attend the entire meeting.
- Presenting authors of accepted abstracts will be given a code to reduce their registration fee to the Early rate if it is no longer available at the time notifications are sent.
- Scheduled abstract sessions will not be changed to accommodate travel schedules.
- Learn more about registration and housing on the [ACR website](#).

Part II: Abstract Submission

Abstract Embargo Policy

Accepted abstracts are available to the public online in advance of the meeting and are published in a special online supplement of the ACR's scientific journal, [Arthritis & Rheumatology](#). Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of PRSYM abstracts on the [ACR/ARP abstract website](#). However, the ACR continues to require that information that goes beyond what is contained in the abstract (e.g., discussion of the abstract done as part of a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until **6:00 PM CT on March 18**.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the ACR abstract embargo policy, please contact the abstract staff at abstracts@rheumatology.org.

Presentation Formats

- Abstracts are considered for plenary presentation, poster breakout presentation, or poster session presentation.
- As English is the designated language for the meeting, the presenting author is required to speak English when presenting.
- If your abstract can only be presented as a poster, please check the appropriate box during the submission process.
- Submitters will be given the option to submit their abstract for consideration as a poster-only presentation during the submission process.
- The acceptance notification email will list the presentation format for each accepted abstract.

Plenary Presentation

- Plenary presentations will be 15-minute podium presentations.
- The presenter will have 12 minutes for presentation and 3 minutes for discussion.
- Presenters will be required to upload their presentations in an electronic format to an online portal where ACR administrators can access the PowerPoint presentation for review.
- Plenary abstract presenters will be required to bring their presentation in an electronic format on-site as backup.
- All slides will be checked for adherence to [ACCME](#) policies by ACR staff prior to providing the presentation to the audiovisual technician on-site.

Plenary Presentation Slide Requirements

- **Slide #1 must be your title slide.**
- **Slide #2 must be your disclosure slide.** Your disclosure statement should list all commercial relationships relevant to your specific talk. Disclosures must never include the use of a trade name or a product group message.
- Do not reference any company/product brand names during your presentation. However, institution logos (e.g., non-company/product logos such as universities, non-profit associations, and government agencies) are allowed in the body of your presentation.
- Abstracts must not contain any advertising, trade names, or product group message.
- Presentations should be in widescreen (16:9) format

Poster Breakout Presentation

- Poster breakout presentations are scheduled as a combination of podium and poster presentation formats.
- The presenter will have a 5-minute podium presentation during a “breakout” session lasting 30 minutes, followed immediately by the poster viewing session in the poster hall.
- These brief talks are to introduce and highlight the work rather than discuss it in detail.
- Questions and further discussion will occur in front of the full poster.
- Presenters will be required to upload their presentations in an electronic format to an online portal where

ACR administrators can access the PowerPoint presentation for review.

- All slides will be checked for adherence to [ACCME](#) policies by ACR staff prior to providing the presentation to the audiovisual technician onsite.
- Presenters will be required to bring their poster to the poster hall by noon CT on Thursday, March 19.
- Breakout posters will be displayed in the Poster Breakout Session section of the poster hall area. Presenters will be scheduled to present at their poster from:
 - Thursday, March 19th
 - 6:00 PM – 7:00 PM CT
 - Friday, March 20th
 - 5:00 PM – 6:00 PM CT

Immediately following their poster breakout session. For additional poster presentation specifications, please see the **Poster Presentation Specifications** section below.

Poster Session Presentation

- Poster presentations facilitate one-on-one interaction between the presenters and attendees.
- Poster sessions will be held from 6:00 PM – 7:00 PM CT on Thursday, March 19 and 5:00 PM – 6:00 PM CT on Friday, March 20.
- Presenters will be scheduled to present their poster in only one viewing session.

ACR Poster Presenter Expectations

- Presenting authors must be available at their poster during the times of their designated poster session to answer questions from attendees.
- Please note that the ACR will be monitoring posters during the presentation hours in an effort to make certain that the ACR is meeting the educational needs and expectations of attendees.
- Please note: The ACR does not have an official poster printing partner and will not offer a poster printing and hanging service in Minneapolis, MN.

Poster Hanging and Dismantling Times:

- Posters must be mounted by noon CT on Thursday, March 19 and dismantled after 6:00 PM CT on Friday, March 20 as outlined in the abstract acceptance notification.
- **IMPORTANT:** The ACR will promptly remove and recycle all posters not picked up by 1:15 PM CT on Saturday, March 21.
- Unclaimed posters will **not** be stored by the ACR.

Poster Presentation Specifications:

- The backboard panel for each poster presentation board measures 42 inches (106.7 cm) high and 90 inches (228.6 cm) wide:



- Posters should be printed horizontally and not exceed the size of the presentation board, 42" x 90".
- A copy of the accepted abstract must be included in the poster or made available to attendees in non-electronic form.
- Text and illustrations must be readable from distances of at least three feet. Use lightweight materials only; heavy articles are difficult to secure.
- Disclosures must never include the use of a trade name or a product group message and must be listed once at the bottom of the poster.
- Posters may be broken down into several smaller portions but must not exceed the size of the presentation board.
- Push pins to mount materials will be available on-site.
- No audiovisual, projection, or computer equipment requiring electrical power will be permitted in the poster session area.
- Poster presenters are permitted to include a QR Code on their poster that allows attendees to scan the code and view the uploaded poster as an electronic copy:

QR Code Tips

- A QR code is a two-dimensional barcode that is readable by smartphones. It allows you to encode a PDF of your poster presentation into a two-dimensional barcode.
- QR codes may be used to share a PDF of your poster presentation with the attendees in lieu of paper handouts.
- To create a QR code, simply search the web for one of the many free online QR code generators.
- ACR staff will be unable to provide assistance with creating QR codes.
- Attendees access the poster from their smartphones by scanning the QR code that you have displayed on your poster.
- QR code readers are available in the Apple App Store and Google Play.

Example:



Presenting Author Responsibilities

At the time of submission, a presenting author must be designated. English is the required language for all meeting presentations.

The presenting author will be the sole point of contact for information regarding the submission and is responsible for the following:

- Ensuring each co-author is aware of the content of the abstract and supports its data. Failure to receive approval from each co-author will result in the abstract being disqualified.
- Ensuring each co-author is aware of the disclosure requirements.
- Adhering to the [Abstract Disclosure Policy](#) and obtaining disclosure information from all co-authors.
- Forwarding ACR policies to each co-author.
- Notifying each co-author of any changes to the program, as communicated by the ACR or ARP, in a timely manner.
- Presenting the abstract or arranging for a co-author to present the abstract if selected. (Only co-authors listed on the accepted abstract may serve as alternate presenting authors.)
- Appointing a co-author to present the abstract in your absence if a schedule conflict is identified before the meeting (i.e., if you have accepted an invitation to participate as an invited speaker or moderator). The ACR will not collect alternate presenter information or make any presenting author corrections to publications.
- Complying with stipulated responsibilities or be subject to corrective action as deemed appropriate by the ACR or ARP leadership.

Abstract Session Schedule Conflicts Policy

- Abstract session and presentation schedules cannot be changed.
- Invited speaker and moderator schedules cannot be changed to accommodate abstract oral or poster presentations.

Presenting Author Affirmations

- The ACR does not condone presentations given by an invited presenter who has not been intimately involved in the development of the data and who cannot meet the criteria for authorship.
- To be eligible to present, presenting authors will be required to confirm agreement with the following affirmation statements at the time of submission:
 - I confirm I had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis and approved the data for presentation.
 - I confirm I made significant contributions to the study design, analysis, or interpretation of results.

Scientific Integrity and ACR Policy Regarding Third-Party Bias

- In accordance with ACR policy, abstracts selected for oral or poster presentation must be scientifically balanced.
- Do not reference any company/product brand names during your presentation. University, non-profit association, or government agency logos are allowed in the body of your presentation.
- The ACR requires that educational materials, such as slides, abstracts, and handouts, do not contain any advertising, trade names, or a product group message.
- Disclosures must never include the use of a trade name or a product group message.
- For oral presentations, disclosures must be listed on the second slide of each presentation.

- For poster presentations, disclosures must be listed once at the bottom of the poster.

Part III: Abstract Permissions Policies

Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of [Arthritis & Rheumatology](#). Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the [ACR website](#). However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of a scientific presentation or presentation of additional new information that will be available at the time of the meeting) **is under embargo until 4:30 PM CT on Wednesday, March 18.**

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the ACR public relations department at pr@rheumatology.org.

Copyright Policy

The Pediatric Rheumatology Symposium is a private event. Programs presented at the meeting are for the education of attendees and purchasers of recorded presentations as authorized by the American College of Rheumatology. The information and materials displayed and presented during this meeting are the property of the ACR and the presenter and cannot be photographed, copied, photocopied, transformed to electronic format, reproduced, or distributed without written permission of the American College of Rheumatology and the presenter. Any use of the program content for commercial purposes, which includes, but is not limited to, oral presentations, audiovisual materials used by speakers, and program handouts, without the written consent of the ACR is prohibited. This policy applies before, during, and after the meeting. The ACR will enforce its intellectual property rights and penalize those who infringe upon it.

Media

Credentialed media attend the Pediatric Rheumatology Symposium to cover stories for consumer, trade, and other media outlets and are identified by a press badge in person. Media has access to all general sessions and limited access (at the discretion of speakers) to roundtable sessions. Attendees who have questions about the ACR's media policies should contact the public relations department at pr@rheumatology.org.

Attendee Photographs and Video Recording Policy

The ACR has made every effort to provide educational content that is easy to access in person and online as a benefit for rheumatology professionals. However, our presenters reserve the right to request no recordings, flash photography, photos of screen images, or screenshots taken of their presentation sessions and can announce this directly to attendees to indicate their preference. Filming, live streaming, and flash photography are strictly prohibited when attending in-person sessions. Press may use handheld audio recorders in sessions for reporting

accuracy only, while respecting all intellectual property rights. Press can take photos with permission from the presenter/speaker. Press can capture photos and audio recordings in a non-disruptive manner. Prohibited press activities online or in person include:

- Unauthorized filming, flash photography, photos of screen images, recording of presentations with third-party software, re-sharing of downloadable content, and live streaming presentations (including posters and exhibits) from your device is strictly prohibited.
- Capturing video of the exhibit hall is strictly prohibited, and interviews should happen outside the exhibit hall.
- Capturing general photos and wide shots of the exhibit hall is prohibited. Press who would like general photos of the exhibit hall can obtain these after the meeting from the ACR by contacting pr@rheumatology.org.
- In public areas, moving video recordings are limited to interviews with presenters/attendees, general b-roll, live video updates, and establishing shots.



Abstract Permissions and Reprints

Copyright law covers all Pediatric Rheumatology Symposium abstracts published by the American College of Rheumatology. All rights reserved. No abstracts may be reproduced in any form or by any means without the prior permission of the publisher, except as permitted under section 107 and 108 of the 1976 United States Copyright Act.

For the purposes of this statement, the term **ACR Abstracts** refers to all PRSYM abstracts as published in *Arthritis & Rheumatology* and posted online.

For the purposes of this statement, the term **ACR Posters** refers to the accepted abstract **POSTER PRESENTATIONS** as presented in the poster hall during PRSYM. **This does not include abstract text published in the online supplement of *Arthritis & Rheumatology*.** All **ACR Posters** are the property of the ACR and the presenting author and cannot be reproduced or distributed without written permission from the ACR and the presenting author.

For the purposes of this statement, the term “reproduce” includes all forms of reproduction, including, but not limited to, print, electronic, and photographed formats.

For the purposes of this statement, the term “presenting author” refers to the author who is designated as the individual who will present the work during PRSYM, as identified through the abstract submission process.

Reproducing ACR Abstracts for Dissemination

Copyright law covers all PRSYM abstracts published by the American College of Rheumatology. All rights reserved. No abstracts may be reproduced in any form or by any means without the prior permission of the publisher, except as permitted under section 107 and 108 of the 1976 United States Copyright Act.

For the purposes of this statement, the term “ACR Abstracts” refers to all PRSYM abstracts as published in *Arthritis & Rheumatology* and posted online.

For the purposes of this statement, the term “ACR Posters” refers to the accepted abstract POSTER PRESENTATIONS as presented in the poster hall during PRSYM. *This does not include abstract text published in the online supplement of Arthritis & Rheumatology.* All ACR Posters are the property of the ACR or the presenting author and cannot be reproduced or distributed without written permission from the ACR and the presenting author.

For the purposes of this statement, the term “reproduce” includes all forms of reproduction including, but not limited to, print, electronic, and photographed formats.

For the purposes of this statement, the term “presenting author” refers to the author who is designated as the individual who will present the work during PRSYM, as identified through the abstract submission process.

Approval Process for ACR Abstracts

1. Excerpts of **ACR Abstracts** may not be reproduced without the prior written permission of the publisher.
2. Permission requests for abstract content and other permission inquiries should be addressed to:

Permissions Department

c/o John Wiley & Sons, Inc.

111 River Street

Hoboken, NJ 07030

Fax: 201-748-6008

Website: wiley.com/go/permissions

- Commercial entities seeking permission to reprint must obtain all materials from the author and/or publisher, John Wiley & Sons, Inc. ACR cannot provide any materials.

Approval Process for ACR Posters

- Reprint requests for the actual poster abstract text published in the *Arthritis & Rheumatology* supplement are considered **ACR Abstracts** and must be submitted to Wiley (see approval process above).
- Requests to reproduce individual ACR posters, poster figures, or booklets of two or more poster presentations must be submitted via email to abstractreprints@rheumatology.org.
- Poster reproduction requests must include the following:
 - Abstract ID Number
 - Abstract Title
 - Presenting Author’s Name
 - A copy of Presenting Author’s written approval (email approval is acceptable)

Reproducing ACR Abstracts and Posters for Dissemination Prior to PRSYM

3. Requests to reproduce abstracts for dissemination prior to PRSYM *will not be approved*.
4. Per the [ACR Embargo Policy](#), academic institutions, private organizations, and companies with products

whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an abstract online. Abstracts may also be presented at other meetings or as the basis for a manuscript.

5. Permission to issue a press release does not require ACR approval. However, it must comply with the [ACR Embargo Policy](#); violation of this policy may result in the abstract being withdrawn from the meeting or other measures deemed appropriate.
6. For more information regarding press releases, please contact the ACR public relations department at pr@rheumatology.org.

Reproducing ACR Abstracts and ACR Poster Presentations for Dissemination During PRSYM

Following approval (see [approval process](#)), guidelines for exhibiting organizations are as follows:

- Exhibiting organizations may disseminate copies of individual ACR Abstracts from its exhibit space. Booklets of abstracts (e.g., two or more) may not be produced. **Any list of QR codes or links to multiple abstracts hosted anywhere other than acrabstracts.org is considered a booklet, and is prohibited.**
- ACR Posters and slides accompanying oral abstract presentations are part of the meeting's scientific content and may not be displayed in an organization's exhibit space.
- Following approval, an exhibiting organization may disseminate information summaries (title/date/time/poster number) of ACR Abstracts from its exhibit space. Summaries may not reference company or product names. Requests for approval must be submitted in writing to abstractreprints@rheumatology.org.
- Presenters may provide an electronic copy of the poster via a QR code (see above for more information).

Reproducing ACR Abstracts and ACR Poster Presentations for Dissemination After PRSYM

Following approval from Wiley ([see approval process](#)), the ACR permits ACR Abstracts (i.e., all abstract content published in the online supplement) to be reprinted and disseminated following PRSYM.

7. Abstracts and booklets of abstracts (e.g., two or more) must include the following statement on the front of the abstract/booklet:
Abstracts reprinted from the Pediatric Rheumatology Symposium, held March 18-21, 2026. The American College of Rheumatology does not guarantee, warrant, or endorse any commercial products or services. Reprinted by (insert name of supporting company).
8. Booklets cannot contain corporate or product logos or any advertisements. **No exceptions.**

ACR Posters

Following approval from the presenting author and the ACR, copies of actual ACR poster presentations (i.e., images of the poster presentation hung in the poster hall) may be reproduced.

9. Reprint requests for the actual poster abstract text published in the *Arthritis & Rheumatology* supplement are considered ACR Abstracts and must be submitted to Wiley (see [approval process](#)).
10. Requests to reproduce individual ACR posters or booklets of poster presentations (e.g., two or more) must be submitted via email to abstractreprints@rheumatology.org.
11. **Poster reproduction requests must include the following:**
 - Abstract ID Number
 - Abstract Title

- Presenting Author's Name
 - A copy of the Presenting Author's written approval (Please note: An email approval from the Presenting Author is acceptable)
12. IMPORTANT: The ACR does not retain and cannot provide poster presentation images.
13. The following statement must be listed under each poster reprint:
- Reprinted from the Pediatric Rheumatology Symposium, held March 18-21, 2026. The American College of Rheumatology does not guarantee, warrant, or endorse any commercial products or services. Reprinted by (insert name of supporting company).*

Disclosure and Content Use

It is suggested, when referencing disclosures in the reprints, that the ACR's disclosure key be added to provide adequate context for abstracts:

- None: Has no relevant financial relationship(s) with ineligible companies to disclose.
- 13. Advisor or Review Panel member
 - 14. Consultant
 - 15. Employee
 - 16. Officer or Board Member
 - 17. Grant/Research Support
 - 18. Speaker/Honoraria includes speakers bureau, symposia, and expert witness
 - 19. Independent Contractor
 - 20. Ownership Interest
 - 21. Royalties
 - 22. Intellectual Property / Patents
 - 23. Stock options or bond holdings in a for-profit corporation or self-directed pension plan
 - 24. Other Financial or Material Support

Use of the ACR Name

14. The names, insignias, logos, and acronyms of the ACR, the ARP, and the Rheumatology Research Foundation are proprietary marks. Use of the names in any fashion, by any entity, for any purpose, is prohibited without the express written permission of the American College of Rheumatology.

Use of the ACR Scientific Program Content

15. Information displayed or presented at all sessions during PRSYM is the property of the ACR or the presenter. Information may not be recorded, photographed, copied, photocopied, transferred to electronic format, reproduced, or distributed without the written permission of the ACR and the presenter.
16. Any use of the program content, which includes but is not limited to oral presentations, audiovisual materials used by speakers, and program handouts, without the written consent of the ACR is prohibited.
17. The ACR's intellectual property rights policy applies before, during, and after the meeting. Violators may be penalized.

Publication

18. Accepted abstracts will be published in an online supplement of [*Arthritis & Rheumatology*](#), an official journal of the American College of Rheumatology.
19. All accepted abstracts will be available on the [ACR Abstracts site](#) several weeks before ACR Convergence.